OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Bowman on Risk Factors for Kidney Cancer Development

April 21st 2025

I. Alex Bowman, MD, discusses recommended strategies for kidney cancer risk reduction.

Dr Choi on the Importance of Education on CAR T-Cell Therapy Manufacturing in Hematologic Malignancies

April 21st 2025

Yeong “Christopher” Choi, PhD, MBA, discusses importance of product and process education to mitigate variability in CAR T-cell therapy manufacturing in hematologic malignancies.

Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer

April 21st 2025

Núria Agustí, MD, discusses patient eligibility in a cohort study assessing adjuvant chemoradiotherapy vs radiotherapy alone in patients with cervical cancer.

Dr Kaklamani on the Efficacy of Inavolisib in HR+, PIK3CA-Mutated Breast Cancer

April 18th 2025

Virginia Kaklamani, MD, DSc, discusses inavolisib's efficacy in PIK3CA-mutated metastatic breast cancer, as well as the importance of biomarker testing.

Dr Zonder on the Importance of Early Screening for Myeloma Among High-Risk Patients

April 18th 2025

Jeffrey Zonder, MD, discusses the need for increased screening for patients who are at higher risk of developing multiple myeloma.

Dr Hernandez-Ilizaliturri on Studying Immunologic Changes With Venetoclax in CLL

April 18th 2025

Francisco J. Hernandez-Ilizaliturri, MD, discusses the rationale behind assessing immunologic changes seen with venetoclax treatment in patients with CLL.

Dr Jhaveri on the Evolving Role of Inavolisib in PIK3CA-Mutated Metastatic Breast Cancer

April 18th 2025

Komal Jhaveri, MD, FACP, discusses the success of the INAVO120 trial of inavolisib/palbociclib/fulvestrant in PIK3CA-mutated metastatic breast cancer.

Dr Alencar on the Ongoing Development of NX-5948 in CLL and B-Cell Malignancies

April 18th 2025

Alvaro Alencar, MD, discusses research needed to clarify the optimal dosing, role, and sequencing of NX-5948 in CLL and other B-cell malignancies.

Dr Matrana on Factors Influencing Upfront Treatment Approaches for RCC

April 18th 2025

Marc R. Matrana, MD, shares his approach to navigating treatment selection when initiating therapy for patients with RCC.

Dr McLornan on the Challenges of Identifying Optimal Timing for Transplantation in Myelofibrosis

April 18th 2025

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, explains the challenges of choosing optimal timing for allogeneic hematopoietic cell transplantation in myelofibrosis.

Dr Shammo on Future Research Investigating Combination Regimens in Myelofibrosis

April 17th 2025

Jamile M. Shammo, MD, discusses future directions for investigating JAK inhibitor–based combination regimens in transfusion-dependent myelofibrosis.

Dr Tolaney on the Optimal Timing of ESR1 Testing in HR+ Breast Cancer

April 17th 2025

Sara M. Tolaney, MD, MPH, discusses the ideal time for patients with HR-positive breast cancer to undergo genetic testing for ESR1 mutations.

Dr Gluz on Ongoing Evaluations of De-Escalated Neoadjuvant Therapy in HR+/HER2+ Breast Cancer

April 17th 2025

Oleg Gluz, MD, discusses research assessing de-escalated chemotherapy and endocrine therapy combinations in HR-positive, HER2-positive early breast cancer.

Dr Morris on the FDA Approval of Nivolumab/Ipilimumab for dMMR/MSI-H Metastatic CRC

April 17th 2025

Van Karlyle Morris, MD, discusses data supporting the FDA approval of nivolumab plus ipilimumab for dMMR/MSI-H unresectable or metastatic CRC.

Dr Richardson on the Role of Quadruplet Regimens in Newly Diagnosed Myeloma

April 17th 2025

Paul G. Richardson, MD, discusses 2 quadruplet regimens for the treatment of patients with newly diagnosed multiple myeloma and changes in administration.

Dr Randall on the Applicability of Bioengineered Bone Marrow Models for Metastasis Control in Sarcoma

April 17th 2025

R. Lor Randall, MD, FACS, discusses the benefits of a 3-dimensional model of the sarcoma tumor microenvironment for studying metastasis control mechanisms.

Dr Randall on the Value of Collaborating With Biomedical Engineers to Develop Preclinical Sarcoma Models

April 16th 2025

R. Lor Randall, MD, FACS, discusses the value of collaboration between oncologists and biomedical engineers to develop preclinical sarcoma models.

Dr Farid on the Rationale for Evaluating MDC-CAR-BCMA001 in R/R Myeloma and AL Amyloidosis

April 16th 2025

Kiavasch Mohammad Nejad Farid, MD, discusses how compassionate use of MDC-CAR-BCMA001 could address unmet needs for multiple myeloma and AL amyloidosis.

Dr Tarantino on Frontline Treatment Considerations in Metastatic HER2+ Breast Cancer

April 16th 2025

Paolo Tarantino, MD, discusses considerations around the frontline treatment of metastatic HER2-positive breast cancer.

Dr Opat on the Unique Mechanism of Action of Sonrotoclax in R/R CLL

April 16th 2025

Stephen Opat, MBBS, explains the unique mechanism of action of sonrotoclax and how it differs from venetoclax for the treatment of patients with relapsed/refractory CLL or SLL.